Print this page
-
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 Bispecific Antibody, in Combination with CHOP (O-CHOP) versus Rituximab in Combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3).
Protocol: 012307Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 Bispecific Antibody, in Combination with CHOP (O-CHOP) versus Rituximab in Combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3).
Protocol: 012307Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma.
Protocol: 012403Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma.
Protocol: 012403Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease.
Protocol: 012411Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease.
Protocol: 012411Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Hodgkin's Lymphoma